MBX Biosciences, Inc. 8-K

What Happened
MBX Biosciences, Inc. announced its financial results for the year ended December 31, 2025 and furnished a related press release on March 12, 2026. The company reported this information on Form 8‑K under Item 2.02 (Results of Operations and Financial Condition). The filing was signed by President and CEO P. Kent Hawryluk.

Key Details

• Company: MBX Biosciences, Inc. (MBX).
• Event: Announced year‑end 2025 financial results; press release furnished as Exhibit 99.1 to the Form 8‑K.
• Filing date: March 12, 2026; reporting period: year ended December 31, 2025.
• Form filing: Item 2.02 (Results of Operations and Financial Condition); exhibits include the press release (Exhibit 99.1) and the Inline XBRL cover page (Exhibit 104).

Why It Matters
This 8‑K provides the company’s headline earnings and financial condition information for the full 2025 year; investors should read the furnished press release for revenue, net income (or loss), cash position, and any management commentary. Those results can affect MBX’s valuation and near‑term trading, and will be important context ahead of the company’s regular periodic filings (e.g., its Form 10‑K) where full audited figures and disclosures will appear.